Nightingale Health expands CE marked blood biomarker service with urine, cerebrospinal fluid and umbilical cord blood services

Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker testing technology, today announced further steps towards widespread expansion and development of its services. In addition to its established CE marked blood biomarker service, Nightingale will be offering metabolomics analysis of urine, cerebrospinal fluid (CSF) and umbilical cord blood samples. These services will deliver comprehensive biomarker data to customers, providing wide-ranging insights into human metabolism and facilitating novel discoveries in biomedical research.

“We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease,” said Teemu Suna, CEO and Founder, Nightingale Health.

Nightingale’s quality management system has been certified to EN ISO 13485. The company’s long-term commitment and continuous investments in quality management have played a central role in its blood biomarker service, and in the development of these new services.

“Our customers trust their valuable sample collections to be assayed with our technology. The quality standard set by EN ISO 13485 is very demanding, but it also guarantees the analysis and results are of the highest level. Quality is a top priority in medical research, and we believe placing it front and center ensures the reliability of novel scientific findings,” continues Suna.

Nightingale Health’s expanded capabilities enables the company to fully cater for researchers working on neurodegenerative conditions, kidney diseases, maternal and fetal health, in addition to those already focused on CVD and diabetes. 

“We’re extremely proud to launch these new services, supporting molecular discoveries via biomarker profiling in cohorts and clinical trials. Nightingale’s novel services utilize high-throughput NMR-based technology, providing cost-effective and scalable solutions. These latest advances will provide new opportunities to researchers for biomarker discovery and translational impact,” saidJanna Ranta, Head of Business, Products and Services, Nightingale Health. 

Nightingale’s current blood biomarker analysis service is built upon an unrivalled scientific foundation, with over 100 peer-reviewed publications in leading biomedical journals. In 2017, the company achieved recognition that its technology is of a clinical grade standard, receiving CE marking for its blood biomarker analysis service.

“Our latest metabolomics offerings take full advantage of our committed focus to quality standards. This means providing highly repeatable metabolite measures, delivered in absolute concentrations and free of batch effects,” continues Ranta.

The first results from Nightingale’s expanded service will be delivered in the fall, with the company currently taking advanced orders from research institutions worldwide. 

Media contact:

Teemu Suna, CEO, Founder

teemu.suna@nightingalehealth.com

+358 40 196 1669

Sales contact:

Janna Ranta, Head of Business, Products and Services

janna.ranta@nightingalehealth.com

+358 44 346 8643

Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis service, quantifying over 220 metabolic blood biomarkers from a single sample. Our metabolomics technology provides a fine-grained snapshot of systemic metabolism and disease effects, measuring biomarkers from multiple pathways in a single experiment. By providing public health researchers with comprehensive insights into the effects of lifestyle factors and future disease risk, we are accelerating the next breakthroughs in precision medicine. In the long term we plan to fully integrate our services into clinical practice, helping to empower patients to follow-up on their own well-being and take proactive steps to stay healthy.

For more information, please visit https://www.nightingalehealth.com

Tags:

About Us

Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.6 trillion dollars annually. Our pioneering precision medicine services, include: effective chronic disease screening, health diagnostics and improving treatment efficacy. By providing our customers with accurate health data, we plan to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy. For more information, please visit https://www.nightingalehealth.com

Subscribe

Media

Media

Quotes

We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease.
Teemu Suna, CEO and Founder, Nightingale Health.